To evaluate the impact of upper tract urothelial carcinoma (UTUC) on BCG response and progression in patients with non-muscle invasive bladder cancer (NMIBC).
We performed an IRB approved review of patients with NMIBC treated with adequate intravesical BCG, as defined by the US FDA, at our institution between 2000 and 2018.